Adaptimmune Therapeutics PLC expected to post a loss of 7 cents a share - Earnings Preview

Adaptimmune Therapeutics

09/08/2024 19:34

* Adaptimmune Therapeutics PLC  ADAP.OQ   ADAP.O  is
expected
to show a rise in quarterly revenue when it reports  results on
August 12 for the period ending June 30 2024
    * The Abingdon Oxfordshire-based  company is expected to
report a
783.4% increase in revenue to $45.318 million from $5.13 million
a year ago, according to the mean estimate from 9 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Adaptimmune Therapeutics
PLC
is for a loss of 7 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $2.00​, above​ its last closing price
of $0.99. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.07       -0.10      -0.18     Missed  -83.7
 Dec. 31 2024  -0.08       -0.10      -0.24     Missed  -140
 Sep. 30 2023  -0.12       -0.14      -0.20     Missed  -45.5​
 Jun. 30 2023  -0.12       -0.13      -0.23     Missed  -72.8
 ​​Jan.        -0.15       -0.15      0.01      Beat    104.1
 1 0001                                                 
 Dec. 31 2022  -0.25       -0.25      -0.18     Beat    27.5​
 Jan. 1 0001   -0.28       -0.24      -0.24     Met     0.7
 Jun. 30 2022  -0.28       -0.25      -0.28     Missed  -14.2
 This summary was machine generated August 9 at 18:33 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)